玻璃体内注射贝伐单抗治疗恶性高血压继发的持续性视网膜病变
Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension.
作者信息
Salman Abdelrahman Gaber
机构信息
Ophthalmology Department, Ain Shams University, Cairo, Egypt.
出版信息
Saudi J Ophthalmol. 2013 Jan;27(1):25-9. doi: 10.1016/j.sjopt.2012.02.005. Epub 2012 Feb 16.
PURPOSE
To evaluate the efficacy and safety of intravitreal bevacizumab (IVB) injection in persistent retinopathy secondary to malignant hypertension (MHT).
PATIENTS AND METHODS
Single IVB injection of 1.25 mg/0.05 ml in 12 cases with persistent retinopathy secondary to MHT more than one month after control of MHT with pre and post injection evaluation of best corrected visual acuity (BCVA) and anatomical outcome up to sixth month and postinjection complications were evaluated.
RESULTS
Progressive reductions in retinal hemorrhages, exudates, cotton-wool spots, and macular star were documented by photography, angiography, and central macular thickness (CMT) measured by optical coherence tomography (OCT) imaging. Decreased macular edema was the most common finding. Improvement or stabilization of visual acuity was noted in all cases.
CONCLUSIONS
In addition to proper medical management of MHT, IVB injection is an effective and safe approach to treat persistent retinopathy associated with MHT.
目的
评估玻璃体内注射贝伐单抗（IVB）治疗恶性高血压（MHT）继发的持续性视网膜病变的疗效和安全性。
患者和方法
对12例MHT继发的持续性视网膜病变患者单次玻璃体内注射1.25mg/0.05ml贝伐单抗，注射前和注射后直至第六个月评估最佳矫正视力（BCVA）和解剖学结果，并评估注射后并发症，这些患者在MHT得到控制一个多月后接受治疗。
结果
通过摄影、血管造影以及光学相干断层扫描（OCT）成像测量的中心黄斑厚度（CMT）记录了视网膜出血、渗出、棉絮斑和黄斑星逐渐减少。黄斑水肿减轻是最常见的发现。所有病例的视力均有改善或稳定。
结论
除了对MHT进行适当的药物治疗外，玻璃体内注射贝伐单抗是治疗与MHT相关的持续性视网膜病变的一种有效且安全的方法。
Zotero 插件